Dennis Wahr, MD
Dennis Wahr, MD is the CEO of Nuvaira which is developing a unique minimally invasive bronchoscopic treatment for patients with chronic obstructive lung disease called Targeted Lung Denervation (TLD).
Prior to joining Nuvaira, Dr. Wahr co-founded Lutonix in 2007 and served as its President and CEO until CR Bard acquired the company in December 2011. Prior to Lutonix, Dr. Wahr co-founded Velocimed in 2001, and served as its President and CEO until its acquisition by St. Jude Medical in 2005.
Dr. Wahr has served on the board of directors of several medical device companies including Accumetrics, IDev, Velocimed, and Lutonix, and he currently serves as chairman of the board for Intact Vascular. Additionally, Dr. Wahr spent two years as a Managing Director with RiverVest Ventures focusing on capital investments in emerging medical technology companies.
Dr. Wahr was an active board-certified interventional cardiologist prior to launching his entrepreneurial career.